The US Food and Drug Administration has cleared the Dexcom G7 15-Day Continuous Glucose Monitor (CGM) for people older than 18 with diabetes. It's the longest-lasting system on the market. The G7 ...
At ATTD 2026, Dexcom (Nasdaq:DXCM) outlined a range of ways in which its continuous glucose monitors (CGMs) benefit people ...
SAN DIEGO--(BUSINESS WIRE)-- DexCom, Inc. (DXCM) (NASDAQ:DXCM), the global leader in glucose biosensing, announced today the FDA has cleared the Dexcom G7 15 Day Continuous Glucose Monitoring System ...
Glucose monitoring specialist Dexcom announced it received FDA clearance for its G7 15 Day continuous glucose monitoring (CGM) system for people 18 and older with type 1, type 2 and gestational ...
BURNABY, British Columbia--(BUSINESS WIRE)--Dexcom, Inc. (NASDAQ: DXCM), a global leader in real-time continuous glucose monitoring (rtCGM) for people with diabetes, announced today that its latest ...
New Ontario Drug Benefit (ODB) coverage means eligible Ontarians who take insulin can now benefit from using Dexcom G7 to simplify management of their diabetes. Ontario residents eligible for ODB and ...
Add Yahoo as a preferred source to see more of our stories on Google. The Dexcom G7 Continuous Glucose Monitoring (CGM) System, shown here with an iPhone and an Apple Watch. (Courtesy of Dexcom) This ...
Dexcom, Inc, has issued a recall for G7 Apps and ONE+ Apps because of a software design error failing to alert users of unexpected sensor failures. This recall ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results